In the effective anticoagulation with factor Xa next generation in the AF–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial, in which amiodarone was used in 11.8% of patients, no significant risk difference was observed in patients who received amiodarone (Steffel et al., 2015). Here, F10 is linked to atrial fibrillation.